Overview Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Status: Not yet recruiting Trial end date: 2022-04-13 Target enrollment: Participant gender: Summary This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease Phase: Phase 2 Details Lead Sponsor: Il-Yang Pharm. Co., Ltd.